Protalix BioTherapeutics, Inc. (NYSE: PLX) announced additional positive data from its phase I/II clinical trial of PRX-102 for the treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Form 8-K Protalix BioTherapeutics For: Aug 10August 10, 2016 7:40 AM Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry DiseaseAugust 10, 2016 7:30 AM Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/ShareAugust 8, 2016 4:56 PM Form 10-Q Protalix BioTherapeutics For: Jun 30August 8, 2016 4:53 PM Form 8-K Protalix BioTherapeutics For: Aug 08August 8, 2016 4:40 PM